UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of
Report (Date of earliest event reported): October 19,
2016
(Exact
Name of Registrant as Specified in Charter)
|
Nevada
|
333-198621
|
46-3312262
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employe Identification No.)
|
|
|
|
|
|
3279
Hardee Avenue
Atlanta,
Georgia
|
|
30341
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (844) 633-6839
Copies
to:
Harvey
Kesner, Esq.
Arthur
S. Marcus, Esq.
Sichenzia
Ross Ference Kesner LLP
61
Broadway, 32nd Floor
New
York, New York 10006
(212)
930-9700
(212)
930-9725 (fax)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
☐
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d 2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
|
Item
5.02
|
Departure
of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers
|
On October 18, 2016, John Blank provided the board of Medovex Corp.
(the “Company”) with his notice of resignation pursuant
to which Mr. Blank resigned from the board of directors (the
“Board”) of the Company. Mr. Blank stated that his
resignation was to allow the Company to appoint another individual
that could contribute more to the Company. Mr. Blank’s
resignation was not a result of any disagreements with the Company
on any matter relating to the Company’s operations, policies
or practices. Mr. Blank is not standing for re-election at the
Company’s Annual Stockholders’ Meeting scheduled for
November 10, 2016 (the “Annual
Meeting”).
On
October 19, 2016, Jon Mogford, PH.D was appointed to fill the
vacancy created by Mr. Blank’s resignation. Dr. Mogford was
designated as a nominee for director in the proxy statement for the
upcoming Annual Meeting. Dr. Mogford serves as the Vice Chancellor
for Research for the Texas A&M University System and provides
research and development leadership to the System’s eleven
universities and seven state agencies encompassing 30,000 faculty
and staff, >135,000 students, a budget of more than $4 billion
and research expenditures of more than $945 million annually. As
the leader of the A&M System Office of Research, he develops
strategic partnerships with external agencies, foundations,
academic institutions, and commercial corporations to enhance the
system’s mission of research, teaching, service and economic
development for the state of Texas.
Prior
to joining the Texas A&M University System in 2011, Dr. Mogford
served as a program manager and then Deputy Director of the Defense
Sciences Office (DSO) of the Defense Advanced Research Projects
Agency (DARPA) in the U.S. Department of Defense. As DSO Deputy
Director, he provided strategic planning and implementation of
≈$400M/year in R&D in the physical, biomedical and
material sciences. He provided leadership to 20 Program Managers in
the development and management of office investments ranging from
the fundamental sciences to commercial transition efforts for both
defense and non-defense applications. Dr. Mogford led expansion of
formal working relationship between DARPA and the FDA to improve
the ability of each organization to meet mission goals, which were
highlighted as a DARPA-FDA-NIH partnership by the White House. He
is the recipient of the Secretary of Defense Medal for Outstanding
Public Service.
His
DARPA programs included scar-free regeneration of wounds, metabolic
control strategies for survival of severe blood loss,
biomarker-responsive biomaterials for drug delivery, stem
cell-based bioreactor production of universal donor red blood
cells, computational design of novel proteins, and active
hemostatic biomaterials for treatment internal and external wounds.
He has authored or co-authored 29 peer-reviewed
publications.
Dr.
Mogford obtained his bachelor’s degree in Zoology from Texas
A&M University and doctorate in Medical Physiology from the
Texas A&M University Health Science Center, College Station,
Texas. His research in vascular physiology continued at the
University of Chicago as a Postdoctoral fellow from 1997-98. Dr.
Mogford transitioned his research focus to the field of wound
healing at Northwestern University, both as a Research Associate
and also as a Research Assistant Professor from 1998-2003. He then
served as a Life Sciences Consultant to DARPA on the
Revolutionizing Prosthetics program from 2003-2005.
There
has not been any transaction or currently proposed transaction, in
which the Company was or is to be a participant and the amount
exceeds $120,000 and in which Dr. Mogford had or will have a direct
or indirect material interest since the beginning of the
Company’s last fiscal year.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
MEDOVEX CORP.
|
|
|
Date: October 19,
2016
|
By:
|
/s/
Jarrett Gorlin
Jarrett
Gorlin
Chief
Executive Officer
|